HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya The site Initiation of the EDCTP funded LIFE project in Tanzania: The study team at the Tanzanian National Institut… https://t.co/FfVS2YGy2G
NIMRMbeya Site initiation visit for Holistic Approach to Unravel Antibacterial Resistance in East Africa #HATUA study at NIMR… https://t.co/ciG1psDCu0
NIMRMbeya RT @MHRPInfo: This week MHRP @wrair is participating in the annual HVTN meeting in Washington, D.C. Here, Deputy Director LTC Julie Ake tal…
NIMRMbeya Maria Mwakatima reviewing an article by Kyle D. Smith et al on "Increased Antifungal Drug Resistance in Clinical Is… https://t.co/9Z2GYTiZPp
© 2017 NIMR - Mbeya Medical Research Center